JP2022549335A - 新規方法 - Google Patents

新規方法 Download PDF

Info

Publication number
JP2022549335A
JP2022549335A JP2022519061A JP2022519061A JP2022549335A JP 2022549335 A JP2022549335 A JP 2022549335A JP 2022519061 A JP2022519061 A JP 2022519061A JP 2022519061 A JP2022519061 A JP 2022519061A JP 2022549335 A JP2022549335 A JP 2022549335A
Authority
JP
Japan
Prior art keywords
compound
formula
alkyl
psychosis
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022519061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549335A5 (enExample
Inventor
イー デイビス，ロバート
スナイダー，グレッチェン
リ，ポン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2022549335A publication Critical patent/JP2022549335A/ja
Publication of JP2022549335A5 publication Critical patent/JP2022549335A5/ja
Priority to JP2025182550A priority Critical patent/JP7821366B1/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2022519061A 2019-09-25 2020-09-25 新規方法 Withdrawn JP2022549335A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182550A JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906042P 2019-09-25 2019-09-25
US62/906,042 2019-09-25
PCT/US2020/052923 WO2021062307A1 (en) 2019-09-25 2020-09-25 Novel methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182550A Division JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Publications (2)

Publication Number Publication Date
JP2022549335A true JP2022549335A (ja) 2022-11-24
JP2022549335A5 JP2022549335A5 (enExample) 2023-10-02

Family

ID=75166462

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519061A Withdrawn JP2022549335A (ja) 2019-09-25 2020-09-25 新規方法
JP2025182550A Active JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182550A Active JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Country Status (4)

Country Link
US (2) US12478623B2 (enExample)
EP (1) EP4034119A4 (enExample)
JP (2) JP2022549335A (enExample)
WO (1) WO2021062307A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3148303C (en) * 2013-12-03 2024-02-27 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
EP4273550A3 (en) 2018-05-17 2024-04-03 Northeastern University Lipid-free anchoring of thermophilic bacteriophage g20c portal adapter into solid-state nanopores
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
US20230312573A1 (en) * 2020-09-04 2023-10-05 Intra-Cellular Therapies, Inc. Novel salts, crystals, and co-crystals
WO2025111568A1 (en) * 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037815A1 (en) * 2005-07-29 2007-02-15 Roger Tung Novel pharmaceutical compounds
WO2019178484A1 (en) * 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
AR024378A1 (es) 1999-06-15 2002-10-02 Du Pont Pharm Co Gamma-carbolinas fusionadas heterociclicas sustituidas
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
KR20030070073A (ko) 2000-12-20 2003-08-27 브리스톨-마이어스스퀴브컴파니 세로토닌 효능제 및 길항제로서의 치환된 피리도인돌
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US20050058703A1 (en) 2003-08-01 2005-03-17 Chang Robert C. Gelatin capsules
RU2401257C2 (ru) 2004-12-07 2010-10-10 Янссен Фармацевтика Н.В. Новые замещенные тетрациклические производные тетрагидрофурана, пирролидина и тетрагидротиофена
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
CA2679754C (en) 2007-03-12 2018-08-07 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
EP2262502A4 (en) 2008-02-05 2011-12-28 Clera Inc Compositions and methods for alleviating depression or improving cognition
SI2262505T1 (sl) 2008-03-12 2015-03-31 Intra-Cellular Therapies, Inc. Substituirana heterociklirano zliti gama-karbolinska trdna snov
WO2009145900A1 (en) 2008-05-27 2009-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
RU2591194C2 (ru) 2010-04-22 2016-07-10 Интра-Селлулар Терапиз, Инк. Органические соединения
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP2015514135A (ja) 2012-04-14 2015-05-18 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
KR20150056608A (ko) 2012-09-14 2015-05-26 아비에 도이치란트 게엠베하 운트 콤파니 카게 트리사이클릭 퀴놀린 및 퀴녹살린 유도체
DK2968320T3 (da) 2013-03-15 2021-02-01 Intra Cellular Therapies Inc Organiske forbindelser
EP3043777B1 (en) 2013-09-10 2020-04-22 Fresh Cut Development, LLC Sublingual buprenorphine spray
CA3148303C (en) 2013-12-03 2024-02-27 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
CA2944512C (en) 2014-04-04 2018-04-24 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines for treatment of central nervous system disorders
US11123311B2 (en) 2016-01-05 2021-09-21 The Regents Of The University Of California Methods of treating mental disorders
PT3407888T (pt) * 2016-01-26 2021-03-19 Intra Cellular Therapies Inc Compostos de piridopirroloquinoxalina, suas composições e utilizações
SI3407889T1 (sl) 2016-03-25 2021-09-30 Intra-Cellular Therapies, Inc. Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema
EP3436016B1 (en) 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
HUE057055T2 (hu) 2016-08-09 2022-04-28 Teva Pharmaceuticals Int Gmbh Lumateperon-ditozilátsó szilárd halmazállapotú formái
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
EP3609501A4 (en) 2017-04-10 2020-08-19 Dr. Reddy's Laboratories Limited AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
JP7223742B2 (ja) * 2017-07-26 2023-02-16 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
CN109867674A (zh) 2017-12-05 2019-06-11 上海度德医药科技有限公司 一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型
DK3768271T3 (da) 2018-03-23 2026-03-02 Intra Cellular Therapies Inc Organiske forbindelser
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) * 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
WO2020112941A2 (en) 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
WO2020182978A1 (en) 2019-03-13 2020-09-17 Sandoz Ag Crystalline salt of a 5-ht2a receptor antagonist
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
EP4744678A2 (en) 2019-12-19 2026-05-20 Intra Cellular Therapies Inc LUMATEPERONE FOR THE TREATMENT OF SCHIZOPHRENIA
IL316924A (en) 2022-05-18 2025-01-01 Intra Cellular Therapies Inc Novel methods
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037815A1 (en) * 2005-07-29 2007-02-15 Roger Tung Novel pharmaceutical compounds
WO2019178484A1 (en) * 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"ITl-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes", EXPERT REVIEW OF NEUROTHERAPEUTICS, vol. 16, no. 6, JPN6024035449, 2016, pages 601 - 614, ISSN: 0005557723 *
"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacolo", CNS SPECTRUMS, MBL COMMUNICATIONS, vol. 24, no. 1, JPN6024035451, August 2019 (2019-08-01), pages 38 - 69, ISSN: 0005557722 *
"Rapid Improvement of Acute Schizophrenia Symptoms After Intravenous Sodium Nitroprusside : A Randomi", JAMA PSYCHIATRY, vol. 70, no. 7, JPN6024035448, 2013, pages 668, ISSN: 0005557724 *

Also Published As

Publication number Publication date
US20260115188A1 (en) 2026-04-30
EP4034119A1 (en) 2022-08-03
WO2021062307A1 (en) 2021-04-01
US12478623B2 (en) 2025-11-25
US20220362241A1 (en) 2022-11-17
JP7821366B1 (ja) 2026-03-05
EP4034119A4 (en) 2023-10-18
JP2026047365A (ja) 2026-03-13

Similar Documents

Publication Publication Date Title
JP7821366B1 (ja) 新規方法
US12409176B2 (en) Methods of treating acute depression
AU2021290277B2 (en) Novel methods
JP7673040B2 (ja) 新規方法
KR102684468B1 (ko) 유기 화합물
JP2021519271A (ja) 有機化合物
JP2020079231A (ja) 有機化合物
CA3102948A1 (en) Novel methods
HK40087977A (en) Deuterated lumateperone for the treatment of the bipolar ii disorder
KR102967223B1 (ko) 신규한 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250625

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20251204